There was a sliver of positive news yesterday, when it was announced that the federal government had signed a deal with Novavax to produce their vaccine in the future National Research Council facility in Montreal. The catch? That facility won’t be completed construction until summer, and then it will require Health Canada approval, so it may not be able to produce new doses until the end of the year – at which point, most Canadians should already be vaccinated using the Pfizer and Moderna doses we’ve contracted for. That doesn’t mean this facility still won’t be for naught – it’s possible we will need booster shots for the other vaccines, possibly do deal with different variants (and Novavax has shown success with the B.1.1.7 variant first spotted in the UK), and it also means that we will be able to produce for export to other countries who will need it.
Of course, this started back in on the same questions about why we weren’t able to produce vaccines domestically earlier, and why this plant is taking so long. Of course, this plant is actually moving faster than is usual – Good Manufacturing Practices facilities to produce vaccines usually take two or three years to build, not a single year, and there are several other facilities under construction across the country for other vaccine candidates. As for the same questions about why we didn’t contract to produce other vaccines here, it was because there were no suitable facilities – particularly from the approved ones. (This NRC facility was in talks to produce the AstraZeneca vaccine, but there is also talk about why the PnuVax facility in Montreal has not yet been tapped – but it may yet be for a future candidate once approved). And for the Pfizer and Moderna vaccines, we simply didn’t have facilities in this country that could produce mRNA vaccines to scale (most existing mRNA production was on a single-dose system for tailored vaccines used for treating particular cancers). And these are things we a) can’t build overnight, and b) didn’t know were even viable because it’s a new technology that had not yet been approved for a vaccine, especially on the scale of the one we’re dealing with now. It would have been a hell of a gamble to build a facility to GMP standards for a vaccine technology that may not have panned out.
Why I’m particularly annoyed about the return of these questions – particularly from the likes of Jagmeet Singh as he appeared on platforms like Power & Politics – is that they pretend that any vaccine facility can produce any vaccine, ignoring that not all vaccines are created equally, or that the technology to produce vaccines isn’t different across platforms. Singh’s notion that a nationalised vaccine producer should have been able to handle this is also farcical because again, what platform would it have bet on? All of them? It’s ridiculous and dishonest – as have been the demands to make the vaccine procurement contracts public (which no other country has done), because all that would do is allow other countries to look at what we paid, and then offer the companies more money to break the contracts with us. (And FFS, both Singh and Erin O’Toole are lawyers and should know this). The kinds of point-scoring that is taking place right now is getting to be beyond the pale, and it’s obscuring the actual kinds of accountability we should be practicing.
Continue reading →